Anuranjana Lucka

Anuranjana Therapeutics is a biotechnology company focused on developing a new class of targeted allosteric inhibitors for the treatment of autoimmune and inflammatory diseases. The company's proprietary platform identifies unique allosteric binding sites to create highly selective small molecule inhibitors, specifically targeting the Janus kinase (JAK) family. By focusing on allosteric rather than orthosteric inhibition, Anuranjana aims to achieve superior selectivity and safety profiles compared to existing JAK inhibitors. Their lead programs are currently in the pre-clinical stage, targeting various dermatological and systemic inflammatory conditions.